levodopa methyl ester has been researched along with benserazide in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bramante, L; Quinn, NP; Ruggieri, S; Steiger, MJ; Stocchi, F | 1 |
| Agnoli, A; Carta, A; Marsden, CD; Quinn, NP; Ruggieri, S; Steiger, MJ; Stocchi, F | 1 |
| Bonastre, M; Chase, TN; Engber, TM; Marin, C; Papa, S; Tolosa, E | 1 |
| Itoh, S; Oo, C | 1 |
| Cai, Y; Liu, Z; Ren, T; Wu, N; Yang, X; Yuan, W | 1 |
| Cai, Y; Liao, M; Liu, Z; Yang, X; Yuan, W; Zheng, R | 1 |
| Bonastre, M; Cortés, R; Giralt, A; Marin, C; Mengod, G; Obeso, JA; Schapira, AH | 1 |
7 other study(ies) available for levodopa methyl ester and benserazide
| Article | Year |
|---|---|
The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson disease.
Topics: Benserazide; Carbidopa; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease | 1992 |
The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon "off" periods in Parkinson's disease.
Topics: Administration, Oral; Aged; Benserazide; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease | 1991 |
MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Dizocilpine Maleate; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Prosencephalon; Rats; Rats, Sprague-Dawley; Rotation | 1996 |
A feasibility study of differential delivery of levodopa ester and benserazide using site-specific intestinal loops in rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Delayed-Action Preparations; Drug Combinations; Feasibility Studies; Infusion Pumps; Intestinal Absorption; Intestinal Mucosa; Intestines; Levodopa; Male; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2010 |
Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Delayed-Action Preparations; Disease Models, Animal; Dopamine Agents; Drug Combinations; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Reaction Time | 2011 |
Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Brain; Dopamine and cAMP-Regulated Phosphoprotein 32; Drug Carriers; Drug Delivery Systems; Dynorphins; Dyskinesia, Drug-Induced; Levodopa; Male; Microscopy, Electron, Scanning; Mitogen-Activated Protein Kinase Kinases; Nanomedicine; Nanoparticles; Particle Size; Phosphorylation; Proto-Oncogene Proteins c-fos; Rats; tau Proteins | 2012 |
Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Benserazide; Benzothiazoles; Corpus Striatum; Hippocampus; Levodopa; Male; Motor Activity; Neurogenesis; Oxidopamine; Parkinsonian Disorders; Pramipexole; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D3; Substantia Nigra; Time Factors | 2014 |